Search results
Results from the WOW.Com Content Network
Bristol-Myers Squibb provides a higher 4.3% yield and an acquisition-driven strategy to counter its 2028 patent cliff. Merck offers a lower but still attractive 3.25% yield, with its specialty ...
Bristol also gains access to RayzeBio's manufacturing site in Indianapolis, Indiana. Bristol will pay $62.50 for each share of RayzeBio in cash, representing a premium of 104% to the stock's last ...
The merger called for Bristol Myers to pay CVR holders an extra $9 per share in cash if it won U.S. Food and Drug Administration approval of Liso-Cel, which is sold as Breyanzi, and Ozanimod by ...
Bristol's quarterly revenue rose 5% to $11.87 billion, exceeding estimates of $11.48 billion. (Reporting By Deena Beasley and Bhanvi Satija in Bengaluru; Editing by Bill Berkrot and Krishna ...
Bristol-Myers reached agreement in August 1964 for a deal under which Mead Johnson would be acquired, with shareholders receiving a mix of common and preferred stock in a deal valued at $240 million. Mead Johnson's net sales in 1966 were $131 million with earnings of $7.3 million.
It was founded in 1927 to produce aluminum splints. The firm is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster. In 2001, Zimmer was spun off from Bristol-Myers Squibb and began trading on the New York Stock Exchange, on August 7, under the ticker symbol “ZMH”. [2]
Charles A. Heimbold Jr. (May 27, 1933 – August 20, 2024) was an American businessman and diplomat, who was Chairman and CEO of Bristol-Myers Squibb Company, and as U.S. Ambassador to Sweden. His son is American musician Pete Francis Heimbold , of Dispatch fame.
Lighter Side. Medicare. News